Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Barden

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Innere Medizin (Heidelberg, Germany)|June 25, 2025
[CAR T cells in solid tumors: resistance mechanisms]Markus Barden, Astrid Holzinger, Hinrich Abken
Cancer Immunology, Immunotherapy : CII|September 11, 2016
The growing world of CAR T cell trials: a systematic reviewAstrid Holzinger, Markus Barden, Hinrich Abken
Cancers|August 10, 2024
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β ReleaseDennis Christoph Harrer, Matthias Eder, Markus Barden, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2021
IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumorsAndreas Hombach, Markus Barden, Lisa Hannappel, et al.
Frontiers in Immunology|December 13, 2023
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challengesDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Journal of Immunological Methods|April 4, 2024
Magnetic CAR T cell purification using an anti-G4S linker antibodyDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Molecular Therapy. Oncology|July 13, 2026
Augmenting CAR T cell functionality and metabolism through CD39 downtuningDennis Christoph Harrer, Jeremy Baldwin, Markus Barden, et al.
Cells|June 25, 2025
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory FashionDennis Christoph Harrer, Tim Schlierkamp-Voosen, Markus Barden, et al.
Frontiers in Immunology|February 23, 2023
CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activationMarkus Barden, Astrid Holzinger, Lukas Velas, et al.
Cells|December 11, 2022
CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopDennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Innere Medizin (Heidelberg, Germany)|June 25, 2025
[CAR T cells in solid tumors: resistance mechanisms]Markus Barden, Astrid Holzinger, Hinrich Abken
Cancer Immunology, Immunotherapy : CII|September 11, 2016
The growing world of CAR T cell trials: a systematic reviewAstrid Holzinger, Markus Barden, Hinrich Abken
Cancers|August 10, 2024
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β ReleaseDennis Christoph Harrer, Matthias Eder, Markus Barden, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2021
IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumorsAndreas Hombach, Markus Barden, Lisa Hannappel, et al.
Frontiers in Immunology|December 13, 2023
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challengesDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Journal of Immunological Methods|April 4, 2024
Magnetic CAR T cell purification using an anti-G4S linker antibodyDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Molecular Therapy. Oncology|July 13, 2026
Augmenting CAR T cell functionality and metabolism through CD39 downtuningDennis Christoph Harrer, Jeremy Baldwin, Markus Barden, et al.
Cells|June 25, 2025
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory FashionDennis Christoph Harrer, Tim Schlierkamp-Voosen, Markus Barden, et al.
Frontiers in Immunology|February 23, 2023
CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activationMarkus Barden, Astrid Holzinger, Lukas Velas, et al.
Cells|December 11, 2022
CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopDennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, et al.
Pageof 2